PSS3 Antibody

What is PS3 and what types of PS3/pS3 antibodies are available for research?

PS3 (Taste 2 receptor member 6 pseudogene) is a human gene encoded by TAS2R6P. Several antibody types targeting PS3-related proteins are available for research purposes, including:

• Anti-Cofilin (pS3) Antibody: Recognizes phosphorylated serine-3 on cofilin protein

• Cofilin (pS3) Antibody: Targets phosphorylated form of cofilin at serine-3

• Anti-Estrogen Inducible Protein pS3 Antibody [SPM573]: Recognizes estrogen-inducible pS3 protein

• Mouse Anti-STAT3 (Phosphorylated Y705) Recombinant Antibody (PS3/1): Targets phosphorylated STAT3

These antibodies are offered in various formulations, including unconjugated forms, and are available in different quantities ranging from 0.03 ml to 0.1 mL depending on the specific product and supplier.

What are the common applications of PS3/pS3 antibodies in laboratory research?

PS3/pS3 antibodies are versatile tools in molecular and cellular research with multiple validated applications:

• Western Blot (WB): For detecting and quantifying target proteins in complex mixtures

• Immunocytochemistry (ICC): For localizing proteins within cultured cells

• Immunofluorescence (IF): For visualizing protein distribution using fluorescent detection

• Immunohistochemistry (IHC): For examining protein expression in tissue sections

• Flow Cytometry (FCM): For analyzing cells in suspension

The reactivity profile of these antibodies varies by product but commonly includes human (Hu), mouse (Ms), rat (Rt), bovine (Bv), and non-human primate (Mk) samples, offering flexibility for comparative studies across species.

How does the PS3 protein signature relate to disease mechanisms in myasthenia gravis?

In myasthenia gravis (MG) research, PS3 refers to a specific protein signature group characterized by:

• High-affinity anti-acetylcholine receptor antibodies (anti-AChR-Abs) that potently activate complement

• Increased disease severity as measured by Quantitative Myasthenia Gravis (QMG) score and MG Activities of Daily Living (MG-ADL) scale

• Treatment resistance, with patients requiring higher steroid doses and more frequent immunosuppressive therapies (ISTs)

This signature appears independent of demographic factors, as PS3 patients showed no differences in age at disease onset, disease duration, or early-onset vs. late-onset MG frequencies compared to other protein signature groups (PS1, PS2, and PS4).

What molecular pathways define the PS3 protein signature group?

The PS3 protein signature is defined by distinct molecular features:

• Enrichment of complement activation pathways

• Enhanced humoral immune response components

• Elevated levels of specific complement proteins (C6, CFHR3, CFHR4)

• Increased abundance of complement-associated proteins (THBS1, ITIH3, IRF7, VTN)

These findings suggest that while all myasthenia gravis patients share antibodies against the acetylcholine receptor, those in the PS3 group produce antibodies with distinct properties that potentially induce stronger complement activation, contributing to increased disease severity.

How can researchers characterize antibody repertoires in patients with the PS3 protein signature?

Researchers investigating PS3 protein signatures can employ immunogenomic analysis techniques to characterize antibody repertoires:

• Isolate peripheral blood mononuclear cells (PBMCs) from patient samples

• Amplify V(D)J sequences of B-cell receptors (BCRs) using short-read amplicon sequencing

• Separately analyze heavy chains and light chains (kappa and lambda)

• Focus analysis on IgG subtypes, as pathogenic anti-AChR antibodies typically belong to this class

• Assess repertoire clonality by quantifying:

  • Number of heavy and light chain clonotypes

  • Frequency of hyperexpanded clones

  • Distribution of immunoglobulin subtypes

  • V(D)J gene usage patterns

This comprehensive approach reveals characteristic features, such as the hyperexpanded antibody repertoire observed in PS3 patients, with fewer BCR clonotypes but higher frequencies of hyperexpanded clones (10-20% of repertoire vs. 0-5% in other groups).

What methodological approaches can reveal complement activation induced by antibodies in PS3 patients?

To investigate complement activation in PS3 patients, researchers can employ these methodological approaches:

• Protein profiling through mass spectrometry of serum samples

• Consensus clustering analysis to identify distinct protein signatures

• Enrichment analysis for gene ontology (GO) terms associated with each protein cluster

• Manual screening of enriched proteins to identify complement-related factors

• Correlation of protein abundance with clinical severity measures (QMG, MG-ADL scores)

• Comparison of treatment responses across patient subgroups to identify treatment-refractory phenotypes

This multi-faceted approach enables identification of PS3-specific protein patterns, such as the observed enrichment of complement components C6, CFHR3, and CFHR4, as well as complement-associated proteins THBS1, ITIH3, IRF7, and VTN.

How can machine learning improve antibody-antigen binding prediction?

Machine learning approaches offer promising avenues for advancing antibody research through binding prediction:

• Library-on-library approaches allow many-to-many relationship analysis between antibodies and antigens

• Models can analyze patterns in binding data to predict interactions between novel antibody-antigen pairs

• Predictive algorithms help overcome the challenge of out-of-distribution prediction (when test antibodies/antigens aren't represented in training data)

These computational approaches complement experimental methods, potentially reducing the cost and time required for antibody development and characterization.

What active learning strategies can enhance antibody-antigen binding experiments?

Active learning strategies can significantly improve experimental efficiency in antibody research:

• Begin with a small labeled subset of antibody-antigen binding data

• Use algorithmic approaches to determine which additional experiments would provide maximum information gain

• Iteratively expand the labeled dataset based on these selections

• Apply specialized algorithms designed for many-to-many relationship data as found in library-on-library screening

Research has demonstrated that optimized active learning strategies can reduce the number of required antigen mutant variants by up to 35% and accelerate the learning process by 28 steps compared to random selection baselines. This approach is particularly valuable given the high cost of generating experimental binding data.

What are key considerations when designing experiments with PS3/pS3 antibodies?

When designing experiments using PS3/pS3 antibodies, researchers should consider:

• Application-specific optimization:

  • For Western Blot: Determine optimal antibody dilution, blocking conditions, and incubation times

  • For Immunohistochemistry: Consider fixation method, antigen retrieval technique, and visualization system

  • For Immunofluorescence: Select appropriate secondary antibodies and controls

• Species cross-reactivity:

  • Verify reactivity with your species of interest (human, mouse, rat, etc.)

  • When working with less common species, validate antibody performance empirically

• Antibody format:

  • Consider whether unconjugated or conjugated antibody formats are more suitable for your application

  • For multi-color applications, select antibodies with compatible fluorophores

Careful consideration of these factors ensures optimal experimental outcomes and reliable data interpretation.

How can researchers distinguish between different protein signatures in autoimmune conditions?

To differentiate protein signatures in autoimmune conditions like myasthenia gravis:

• Employ comprehensive proteomic analysis of patient samples

• Apply consensus clustering to identify distinct patient subgroups

• Correlate protein signatures with clinical parameters (disease severity, treatment response)

• Control for confounding factors through matched analysis:

  • Compare patients on similar treatment regimens

  • Account for disease duration and onset age

  • Consider comorbidities (e.g., thymoma)

• Validate findings through targeted analysis of specific protein pathways:

  • Complement activation markers

  • Immunoglobulin profiles

  • B-cell receptor repertoire characteristics

This multi-dimensional approach enables identification of clinically relevant patient subgroups that may benefit from tailored therapeutic strategies.